Palbociclib in Patients With Pancreatic and Biliary Cancer With

The Targeted Agent and Profiling Utilization Registry (TAPUR) Study identifies signals of antitumor activity of commercially available targeted agents in patients with advanced cancers that harbor genomic alterations known as drug targets. In this article, data from two cohorts of patients with pancreatic and biliary cancers with Eligible patients age 12 years and older with advanced measurable or evaluable solid tumors are provided treatment according to protocol-specified genomic matching rules. The primary study end point is objective response or stable disease of at least 16 weeks duration. For each cohort, a Simon two-stage design was used with a futility evaluation after 10 patients. Secondary end points include safety, progression-free survival (PFS), and overall survival (OS). Between July 2016 and November 2017, 12 and 10 patients with pancreatic and biliary cancer, respectively, with Palbociclib monotherapy does not have clinical activity in patients with advanced pancreatic or biliary cancers with